SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SINTX plans to update investors on its silicon nitride medical technologies and commercial strategy at the 2026 H.C. Wainwright conference.

Rhea-AI Summary

SINTX Technologies (SINT) will present at the 28th Annual H.C. Wainwright Global Investment Conference from September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.

Chief Investment Officer Gregg Honigblum and President Ryan Elmore will deliver a company presentation and hold one-on-one meetings with investors. The presentation is expected to cover progress in commercializing the FDA-cleared SINAPTIC® Foot & Ankle Implant System, expansion of proprietary silicon nitride technology adoption, growth in contract manufacturing activities, and strategic initiatives to broaden commercial opportunities and support long-term shareholder value.

Investors can request meetings through their H.C. Wainwright representative, email meetings@hcwco.com, or contact SINTX Investor Relations at IR@sintx.com.

Key Terms

fda-cleared, silicon nitride

2 terms

fda-cleared regulatory

"commercializing its FDA-cleared SINAPTIC® Foot & Ankle Implant System"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

silicon nitride technical

"expanding adoption of its proprietary silicon nitride technology"

A very hard, lightweight ceramic material made from silicon and nitrogen that resists heat, wear and corrosion. Think of it as industrial-grade pottery that can take extreme conditions where metals or plastics would fail. For investors, its use in high-performance bearings, engine parts, electronics and medical implants can signal exposure to premium, durable products, specialized manufacturing margins and markets with long-term replacement cycles.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, Utah, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.

Gregg Honigblum, Chief Investment Officer, and Ryan Elmore, President of SINTX, will deliver a company presentation and participate in one-on-one meetings with investors throughout the conference. The presentation will highlight SINTX’s progress in commercializing its FDA-cleared SINAPTIC^® Foot & Ankle Implant System, expanding adoption of its proprietary silicon nitride technology, growing its contract manufacturing activities, and advancing strategic initiatives designed to broaden the Company’s commercial opportunities and support long-term shareholder value.

Event Details
Conference: 28th Annual H.C. Wainwright Global Investment Conference
Date: September 14–16, 2026
Location: Lotte New York Palace Hotel, New York City

Investors interested in scheduling a one-on-one meeting with SINTX management are encouraged to contact their H.C. Wainwright representative, email meetings@hcwco.com, or contact SINTX Investor Relations at IR@sintx.com.

About SINTX Technologies, Inc.

Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities, and strategic industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SINAPTIC^® Foot & Ankle Implant System for reconstructive surgery.

SINTX Contacts:
SINTX Technologies, Inc.
801.839.3502
IR@sintx.com

FAQ

Where and when is the H.C. Wainwright Global Investment Conference taking place?

The 28th Annual H.C. Wainwright Global Investment Conference will be held from September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.

Who will represent SINTX Technologies at the conference?

Gregg Honigblum, Chief Investment Officer, and Ryan Elmore, President of SINTX, will deliver the company presentation and participate in one-on-one investor meetings.

What topics will SINTX cover in its conference presentation?

The company plans to highlight progress in commercializing its FDA-cleared SINAPTIC® Foot & Ankle Implant System, expanding adoption of its proprietary silicon nitride technology, growing contract manufacturing activities, and advancing strategic initiatives aimed at broadening commercial opportunities and supporting long-term shareholder value.

How can investors schedule one-on-one meetings with SINTX management?

Investors may contact their H.C. Wainwright representative, email meetings@hcwco.com, or reach SINTX Investor Relations at IR@sintx.com to request a one-on-one meeting.

What does SINTX Technologies focus on as a business?

SINTX is an advanced ceramics and biomaterials company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. Its business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities.

What key medical product does SINTX currently offer?

SINTX’s product portfolio includes the FDA-cleared SINAPTIC® Foot & Ankle Implant System for reconstructive surgery.